Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Fortunato D’Ancona is active.

Publication


Featured researches published by Fortunato D’Ancona.


Emerging Infectious Diseases | 2002

Tularemia Outbreak Investigation in Kosovo: Case Control and Environmental Studies

Ralf Reintjes; Isuf Dedushaj; Ardiana Gjini; Tine Rikke Jorgensen; Benvon Cotter; Alfons Lieftucht; Fortunato D’Ancona; David T. Dennis; Michael A. Kosoy; Gjyle Mulliqi-Osmani; Roland Grunow; Ariana Kalaveshi; Luljeta Gashi; Isme Humolli

A large outbreak of tularemia occurred in Kosovo in the early postwar period, 1999-2000. Epidemiologic and environmental investigations were conducted to identify sources of infection, modes of transmission, and household risk factors. Case and control status was verified by enzyme-linked immunosorbent assay, Western blot, and microagglutination assay. A total of 327 serologically confirmed cases of tularemia pharyngitis and cervical lymphadenitis were identified in 21 of 29 Kosovo municipalities. Matched analysis of 46 case households and 76 control households suggested that infection was transmitted through contaminated food or water and that the source of infection was rodents. Environmental circumstances in war-torn Kosovo led to epizootic rodent tularemia and its spread to resettled rural populations living under circumstances of substandard housing, hygiene, and sanitation.


Eurosurveillance | 2014

Seasonal influenza immunisation in Europe. Overview of recommendations and vaccination coverage for three seasons: pre-pandemic (2008/09), pandemic (2009/10) and post-pandemic (2010/11).

Jolita Mereckiene; Suzanne Cotter; A Nicoll; P L Lopalco; Teymur Noori; J T Weber; Fortunato D’Ancona; D Lévy-Bruhl; L Dematte; Cristina Giambi; Palle Valentiner-Branth; I. Stankiewicz; Eva Appelgren; Darina O’Flanagan

Since 2008, annual surveys of influenza vaccination policies, practices and coverage have been undertaken in 29 European Union (EU)/ European Economic Area (EEA) countries. After 2009, this monitored the impact of European Council recommendation to increase vaccination coverage to 75% among risk groups. This paper summarises the results of three seasonal influenza seasons: 2008/09, 2009/10 and 2010/11. In 2008/09, 27/29 countries completed the survey; in 2009/10 and 2010/11, 28/29 completed it. All or almost all countries recommended vaccination of older people (defined as those aged ≥50, ≥55, ≥59, ≥60 or ≥65 years), and people aged ≥6 months with clinical risk and healthcare workers. A total of 23 countries provided vaccination coverage data for older people, but only 7 and 10 had data for the clinical risk groups and healthcare workers, respectively. The number of countries recommending vaccination for some or all pregnant women increased from 10 in 2008/09 to 22 in 2010/11. Only three countries could report coverage among pregnant women. Seasonal influenza vaccination coverage during and after the pandemic season in older people and clinical groups remained unchanged in countries with higher coverage. However, small decreases were seen in most countries during this period. The results of the surveys indicate that most EU/EEA countries recommend influenza vaccination for the main target groups; however, only a few countries have achieved the target of 75% coverage among risk groups. Coverage among healthcare workers remained low.


Vaccine | 2011

Reliable surveillance of tick-borne encephalitis in European countries is necessary to improve the quality of vaccine recommendations.

Pawel Stefanoff; Polkowska A; Cristina Giambi; D Lévy-Bruhl; Darina O’Flanagan; L Dematte; Pier Luigi Lopalco; Jolita Mereckiene; Kari Johansen; Fortunato D’Ancona

In July-November 2009, 26 European Union (EU) Member States (MSs), Norway and Iceland, participated in a survey seeking information on national tick-borne encephalitis (TBE) vaccination recommendations. Information on TBE surveillance, methods used to ascertain endemic areas, vaccination recommendations, vaccine coverage and methods of monitoring of vaccine coverage were obtained. Sixteen countries (57%) reported presence of TBE endemic areas on their territory. Vaccination against TBE was recommended for the general population in 8 (28%) countries, for occupational risk groups - in 13 (46%) countries, and for tourists going abroad - in 22 (78%) countries. Although vaccination recommendations for country residents, and for tourists always referred to endemic areas, there was no uniform, standardized method used to define endemic areas. For this reason, clear recommendations for tourists need to be developed, and standardized surveillance directed to efficient assessment of TBE risk need to be implemented in European countries.


Emerging Infectious Diseases | 2008

Chikungunya and Dengue Viruses in Travelers

Loredana Nicoletti; Massimo Ciccozzi; Antonella Marchi; Cristiano Fioretini; Patrizia Martucci; Fortunato D’Ancona; Marta Luisa Ciofi degli Atti; Maria Grazia Pompa; Giovanni Rezza; Maria Grazia Ciufolini

To the Editor: Chikungunya virus (CHIKV), an arthropod-borne virus transmitted to humans by Aedes spp. mosquitoes, was first isolated in Tanzania (Tanganyika) in 1953 (1). Various outbreaks have since occurred in Africa, Southeast Asia, and India (2). CHIKV has recently been reported in a large area in the Indian Ocean islands and the Indian subcontinent. After an outbreak in Kenya in 2004, other outbreaks occurred in early 2005 on the Comoros Islands, Reunion, and other islands in the southwestern Indian Ocean; the epidemic then spread to India (3,4). Molecular analysis showed that the epidemic was caused by a variant of the Central/East African CHIKV genotype (5,6). Internet surveillance networks provided information on epidemics in real time, alerting clinicians in the industrialized world to the spread of CHIKV and enabling them to more easily diagnose infection among travelers with fevers (7). We report results of diagnostic tests and analysis of predictors of infection among persons in Italy with symptoms suggestive of CHIKV infection who had traveled to potentially affected areas. Dengue virus (DENV) is endemic to many of these areas. We studied travelers or migrants from areas to which CHIKV infection is endemic (i.e., sub-Saharan Africa) or areas currently affected by outbreaks (i.e., the Indian Ocean islands, India) who had symptoms suggestive of infection (i.e., fever and arthralgia with or without a rash) from January 2006 through March 2007. At least 1 blood sample was collected from each patient and stored at –80°C before testing for CHIKV and DENV. Median lag between onset of symptoms and date of blood collection was 22 days (range 3–179 days). Two samples (acute phase and convalescence phase) were available from 5 patients. Serologic diagnosis of CHIKV infection was determined by hemagglutination inhibition (HI) test and confirmed by plaque-reduction neutralization test (8). Serodiagnosis of DENV infection was conducted by using the HI test and an immunoglobulin M ELISA (Focus Diagnostics, Cypress, CA, USA). A case-report form containing information about age, sex, countries visited, travel dates, and date of onset of symptoms was completed for each patient. Seventy-six persons participated in the study; 55.3% were male, median age was 39 years (range 1–69 years), and most (80.3%) were Italian (Table). A total of 29 (38.2%) were positive for CHIKV, and 13 (17.1%) were positive for DENV; 34 (44.7%) were negative for both viruses. Of the 29 CHIKV-positive persons, 22 (75.9%) had visited the Indian Ocean islands (Mauritius, Reunion, and Madagascar), 5 had visited Asia, and 2 had visited Africa. Travelers from Indian Ocean islands had a higher risk for CHIKV infection than those who had visited Africa (odds ratio [OR] 11.0, 95% confidence interval [CI] 1.60–119.13) or Asia (OR 17.05, 95% CI 4.31–73.05). Persons who had visited Asia had a higher risk for DENV infection (OR 8.36; 95% CI 1.58–81.73) than those who had visited other areas. Table Characteristics of 76 travelers studied The 5 persons who were infected with CHIKV in Asia had visited India (i.e., the most visited country [21 travelers]). However, persons who visited the Indian Ocean islands had a higher risk of being CHIKV positive than those who had visited India (OR 8.8, 95% CI 2.09–39.86). A rash was associated with CHIKV infection and was >8× more likely to be reported by CHIKV-positive persons than CHIKV-negative persons (OR 7.03, 95% CI 2.23–22.93). Moreover, rash was observed in 65% of CHIKV-positive cases and 31% of DENV-positive cases, but the difference was not statistically significant because of the small sample size (OR 4.28, 95% CI 0.88–23.23). None of the other patient’s characteristics was associated with infection with CHIKV or DENV. A limitation of our study was that only 5 patients had documented seroconversion for CHIKV. However, high titers were found in all but 1 patient (>1,280 in 21 patients and 640 in 2 patients). This patient, who had a titer of 80, was an Italian who had probably not been previously exposed to CHIKV. Thus, the risk for misclassification was low. PCR for early detection of infection was not used because only 3 persons were tested within 10 days of symptom onset. Two of these persons, who were tested 7 days after symptom onset, already had antibodies to CHIKV. In conclusion, a high proportion of travelers with symptoms of CHIKV infection who returned from areas with outbreaks of this infection or where this virus was endemic were seropositive. A lower proportion of patients had antibodies to DENV. CHIKV-positive patients were more likely to have a rash than those negative for both CHIKV and DENV. As suggested by previous studies (9), a rash was more common among CHIKV-positive patients than in DENV-infected patients, but the difference was not significant. Our study suggests that identification of predictors of infection with CHIKV is feasible, although it is complicated by cocirculation of DENV in the same areas.


Eurosurveillance | 2016

Increased incidence of invasive meningococcal disease of serogroup C / clonal complex 11, Tuscany, Italy, 2015 to 2016.

Paola Stefanelli; Alessandro Miglietta; Patrizio Pezzotti; Cecilia Fazio; Arianna Neri; Paola Vacca; Fabio Voller; Fortunato D’Ancona; Raniero Guerra; Stefania Iannazzo; Maria Grazia Pompa; Giovanni Rezza

We report an increase of serogroup C Neisseria meningitidis invasive meningococcal disease in Tuscany. From January 2015 to end February 2016, 43 cases were reported, among which 10 were fatal, compared to two cases caused by serogroup C recorded in 2014 and three in 2013. No secondary cases occurred. Thirty-five strains belonged to C:P1.5-1,10-8:F3-6:ST-11(cc11). Control measures have been adopted and immunisation campaigns implemented. Studies on risk factors and carriage are ongoing.


Expert Review of Vaccines | 2014

The issue of mandatory vaccination for healthcare workers in Europe

Emmanouil Galanakis; Fortunato D’Ancona; Andreas Jansen; Pier Luigi Lopalco

Mandatory policies have occasionally been implemented, targeting optimal vaccination uptake among healthcare workers (HCWs). Herein, we analyze the existing recommendations in European countries and discuss the feasibility of implementing mandatory vaccination for HCWs. As reflected by a survey among vaccine experts from 29 European countries, guidelines on HCW vaccination were issued in all countries, though with substantial differences in targeted diseases, HCW groups and type of recommendation. Mandatory policies were only exceptionally implemented. Results from a second survey suggested that such policies would not become easily adopted, and recommendations might work better if focusing on specific HCW groups and appropriate diseases such as hepatitis B, influenza and measles. In conclusion, guidelines for HCW vaccination, but not mandatory policies, are widely adopted in Europe. Recommendations targeting specific HCW groups and diseases might be better accepted and facilitate higher vaccine uptake than policies vaguely targeting all HCW groups.


Vaccine | 2015

Actions improving HPV vaccination uptake – Results from a national survey in Italy

Cristina Giambi; Martina Del Manso; Fortunato D’Ancona; Barbara De Mei; Ilaria Giovannelli; Chiara Cattaneo; Valentina Possenti; Silvia Declich

BACKGROUND In Italy, HPV vaccination is offered to 11-year-old girls since 2007. In 2012 coverage was 69%. Strategies for offering and promoting HPV vaccination and coverage rates (26-85%) vary among Regions and Local Health Authorities (LHAs). We conducted a national study to identify strategies to improve HPV vaccination uptake. METHODS In 2011-2012 we invited the 178 LHAs to fill a web-questionnaire, inquiring implementation of HPV vaccination campaigns (immunization practices, logistics of vaccine delivery, training, activities to promote vaccination, barriers, local context). We described type of offer and vaccination promotion in each LHA and studied the association of these factors with vaccination coverage rates. RESULTS We analyzed 133 questionnaires. The communication tools more frequently used to promote vaccination were: brochures/leaflets (92% of LHAs), fliers/posters (72%). Television (24%) and radio (15%) were less used. Using ≥3 communication channels was associated to a coverage ≥70% (ORadj=5.9, 95%CI 2.0-17.4). The probability to reach a coverage ≥70% was higher if the invitation letter indicated a pre-assigned date for HPV vaccination (ORadj=7.0, 95%CI 1.2-39.8) and >1 recall for non-respondents was planned (ORadj=4.1, 95%CI 1.8-9.3). Immunization services and paediatricians were involved in informative and training activities in most LHAs (80-90%), instead general practitioners, women and familys healthcare services and public gynaecologists in 60-70%, cervical cancer screening services and private gynaecologists in 20-40%. The main factors that negatively affected vaccination uptake were: poor participation to training events of professional profiles different from personnel of immunization services (reported by 58% LHAs), their mistrust towards HPV vaccination (55%) and insufficient resources (56%). CONCLUSION The synergy of multiple interventions is necessary for a successful vaccination programme. Practices such as pre-assigning vaccination date and repeatedly recalling non-respondents could improve vaccination uptake. Efforts are required to strengthen the training of different professional profiles and services and encourage their collaboration. Economical resources are needed to promote vaccination.


PLOS ONE | 2015

Epidemiological and Molecular Characterization of Invasive Meningococcal Disease in Italy, 2008/09-2012/13

Arianna Neri; Patrizio Pezzotti; Cecilia Fazio; Paola Vacca; Fortunato D’Ancona; Maria Grazia Caporali; Paola Stefanelli

Background Following the introduction of meningococcal serogroup C conjugate vaccine in Italy in 2005, changes in the epidemiology of Invasive Meningococcal Disease (IMD) were expected. The study aims were to describe the epidemiological trend and to characterize the isolates collected during the period 2008/09-2012/13 by multilocus sequence typing (MLST). Data on laboratory confirmed meningococcal diseases from National Surveillance System of IMD were reported. Methods Poisson regression models were used to estimate the incidence rate over time. Serogrouping and MLST were performed following published methods. Results The incidence rate of laboratory confirmed meningococcal disease decreased from 0.33 per 100,000 population in 2008/09 to 0.25 per 100,000 population in 2012/13. The serogroup B incidence rate was significantly higher (p<0.01) than that of other serogroups, among all age groups. The significant decrease of the IMD incidence rate (p = 0.01) reflects the decrease of serogroup B and C, in particular among individuals aged 15–24 years old (p<0.01). On the other hand, serogroup Y incidence increased during the period (from 0.01/100,000 in 2008/09 to 0.02/100,000 in 2012/13, p = 0.05). Molecular characterizations revealed that ST–41/44 cc and ST–11 cc were the main clonal complexes identified among serogroup B and C isolates, respectively. In particular, ST–41/44 cc was predominant in all age groups, whereas ST–11 cc was not identified in infants less than 1 year of age. Conclusions IMD incidence declined in Italy and serogroup B caused most of the IMD cases, with infants having the highest risk of disease. Continued surveillance is needed to provide information concerning further changes in circulating meningococci with special regard to serogroup distribution. Moreover, knowledge of meningococcal genotypes is essential to detect hyper-invasive strains.


Eurosurveillance | 2018

Introduction of new and reinforcement of existing compulsory vaccinations in Italy: first evaluation of the impact on vaccination coverage in 2017

Fortunato D’Ancona; Claudio D’Amario; Francesco Maraglino; Giovanni Rezza; Walter Ricciardi; Stefania Iannazzo

In June 2017, a decree-law to increase the number of mandatory vaccinations from 4 to 10 for minors up to 16-years-old was issued in Italy. The vaccination coverage for 2017 showed a positive impact for all the vaccines, particularly for the measles, mumps and rubella vaccine at 91.6% for the year 2017, showing a 4.4% increase compared with 2016 (87.2%). Continued monitoring is needed to evaluate the medium to long-term effects of the law.


Microbiologia Medica | 2006

MICRONET: UNA RETE INFORMATIZZATA PER LA RACCOLTA DATI MULTICENTRICA DA LABORATORI DI MICROBIOLOGIA

Fortunato D’Ancona; Caterina Rizzo; Valeria Alfonsi; Ml. Ciofi Degli Atti; Gruppo di Lavoro Micronet

Microbiologia Medica 165 in pazienti ospedalizzati. È segnalato all’origine di epidemie nosocomiali da fonte comune, identificata per lo più in soluzioni disinfettanti contaminate. Scopo della presente ricerca è lo studio epidemiologico e molecolare di un evento epidemico da B. cepacia occorso in due reparti di terapia intensiva del Policlinico di Modena, da gennaio 2005 a marzo 2006. Metodi. L’indagine epidemiologica ha coinvolto 38 pazienti, tutti con colture positive dei materiali respiratori, 29 colonizzati e 9 affetti da polmonite. Sono stati conservati e studiati tutti i ceppi di B. cepacia isolati nel periodo suddetto da tutti i reparti di degenza dell’ospedale ed è stata ricercata una fonte comune dei casi a partire da numerosi campioni di sorveglianza. Complessivamente 58 stipiti sono stati sottoposti a tipizzazione molecolare con metodo RAPD-PCR e all’analisi filogenetica. Risultati. Dopo un anno dall’inizio dell’evento, un ceppo di B. cepacia si ritrovava nell’acqua deionizzata utilizzata dalla Farmacia dell’ospedale nella preparazione di un collutorio a base di clorexidina destinato ai pazienti dei reparti di rianimazione. Tutti i ceppi clinici e quelli isolati dal collutorio (clorexidina al 4%) appartenevano al medesimo genotipo. Genotipi differenti si ritrovavano invece negli isolati dall’acqua deionizzata. Conclusioni. Verosimilmente l’azione della clorexidina ha selezionato un clone resistente a partire dalla popolazione microbica presente nell’acqua, responsabile dei casi di infezione e di colonizzazione. La sospensione dell’uso del collutorio ha determinato la cessazione immediata degli isolamenti, confermando il rapporto tra il disinfettante e l’insorgenza dei casi già indicato dai risultati dalla tipizzazione molecolare. Una sola segnalazione in letteratura associa infezioni respiratorie da B. cepacia all’uso di un collutorio a base di clorexidina (1). Lo studio di questo episodio conferma il ruolo di colluttori non alcolici nel determinare infezioni in pazienti sottoposti a ventilazione forzata e sottolinea il valore di accurate indagini epidemiologiche nella risoluzione di un evento epidemico. CO2.3

Collaboration


Dive into the Fortunato D’Ancona's collaboration.

Top Co-Authors

Avatar

Annalisa Pantosti

Istituto Superiore di Sanità

View shared research outputs
Top Co-Authors

Avatar

Cristina Giambi

Istituto Superiore di Sanità

View shared research outputs
Top Co-Authors

Avatar

Giovanni Rezza

Istituto Superiore di Sanità

View shared research outputs
Top Co-Authors

Avatar

Arianna Neri

Istituto Superiore di Sanità

View shared research outputs
Top Co-Authors

Avatar

Cecilia Fazio

Istituto Superiore di Sanità

View shared research outputs
Top Co-Authors

Avatar

F. D’Ambrosio

Istituto Superiore di Sanità

View shared research outputs
Top Co-Authors

Avatar

Maria Grazia Caporali

Istituto Superiore di Sanità

View shared research outputs
Top Co-Authors

Avatar

Monica Monaco

Istituto Superiore di Sanità

View shared research outputs
Top Co-Authors

Avatar

Paola Stefanelli

Istituto Superiore di Sanità

View shared research outputs
Top Co-Authors

Avatar

Patrizio Pezzotti

Istituto Superiore di Sanità

View shared research outputs
Researchain Logo
Decentralizing Knowledge